miragenews.com
Microbiome Breakthrough: New Crohn's Treatment Unveiled
This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and potentially delay relapse.
If proven safe and effective in humans, the approach could offer a non-pharmacologic option to maintain remission.
People with Crohn's disease (including adolescents and adults), caregivers and parents of pediatric patients, gastroenterologists and clinical researchers interested in diet- and microbiome-based therapies, and people considering clinical trial participation.
What To Know
Researchers at Technical University of Munich and LMU report that exclusive enteral nutrition (EEN) changes the gut microbiome in ways that reduce inflammation in models.
They are starting a clinical study (EEN-RICH) testing whether combining EEN with fecal microbiome transfer (FMT) — given as screened donor capsules after the liquid diet — can prolong remission in people with Crohn's disease.
The published preclinical work showed microbiome changes from the formula protected mice from inflammation when transferred, and the new trial will test safety, feasibility, and whether the approach stabilizes disease-quiescence or delays relapse.
This article describes early-stage translational research and an ongoing clinical study rather than established new therapy. The intervention combines an already used dietary treatment (EEN) with screened donor fecal microbiome transfer in capsule form; the team is recruiting participants and manufacturing capsules at a university hospital.
The investigators state their main questions are safety, feasibility, and whether the microbiome can be durably reshaped after EEN to maintain remission. If you are considering trial participation, note this report does not provide results from the human study yet.
Clinical details, eligibility, and results will be available from the trial team and peer-reviewed publications when complete. For current care decisions, discuss with your gastroenterology team rather than changing treatment based on this news.
The original source links to the published Cell Host & Microbe paper describing the mechanistic work and to the EEN-RICH trial site for more information on participation.
The article reports on preclinical findings and the start of a clinical study (EEN-RICH). The human trial is ongoing and aims to assess safety, feasibility, and effect on relapse; no clinical outcomes from humans are reported here. FMT has established uses in other conditions but remains investigational for Crohn's disease; participation requires screening and oversight.
Read the original published study and trial registry for full methods and eligibility.
